PEAK6
DFTX

PEAK6’s Definium Therapeutics DFTX Stock Holding History

PEAK6’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,915
Closed -$102K – 3267
2025
Q2 		$70.8K Sell
10,915
-2,087
-16% -$13.7K ﹤0.01% 2666
2025
Q1 		$76.1K Buy
13,002
+4,907
+61% +$35.1K ﹤0.01% 2640
2024
Q4 		$56.3K Buy
+8,095
New +$55.7K ﹤0.01% 2822

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PEAK6's DFTX Position: Q3 2025 in Review

PEAK6 sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 10,915 shares — an estimated $102K sold.

PEAK6 first reported a position in DFTX in Q4 2024 and held it in 3 quarters. The position peaked at $76.1K in Q1 2025. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • PEAK6 reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PEAK6 sold 10,915 Definium Therapeutics shares in Q3 2025, an estimated $102K.
  • PEAK6 first reported a position in Definium Therapeutics in Q4 2024 and held it in 3 quarters.
  • PEAK6's Definium Therapeutics position peaked at $76.1K in Q1 2025.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.